Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | UTS2R | Q9UKP6 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17835801 | 1.00 | SLC6A9 (0.56) | SLC6A9MAPTUTS2RMEN1CYP1A2 | |
| SCHEMBL17835738 | 0.91 | SLC6A9 (0.56) | SLC6A9TSHR | |
| SCHEMBL17835590 | 0.91 | SLC6A9 (0.56) | SLC6A9TSHR | |
| SCHEMBL17835592 | 0.91 | SLC6A9 (0.56) | SLC6A9TSHR | |
| SCHEMBL17835644 | 0.88 | NOX1 (0.56) | SLC6A9MAPTKMT2ANOX1 | |
| SCHEMBL17835645 | 0.88 | NOX1 (0.56) | SLC6A9MAPTKMT2ANOX1 | |
| SCHEMBL17835816 | 0.87 | SLC6A9 (0.52) | SLC6A9SLC6A4NOX1 | |
| SCHEMBL17835817 | 0.87 | SLC6A9 (0.52) | SLC6A9SLC6A4NOX1 | |
| SCHEMBL17835845 | 0.86 | MAPT (0.49) | SLC6A9MAPTMEN1CYP1A2CYP3A4 | |
| SCHEMBL17835846 | 0.86 | MAPT (0.49) | SLC6A9MAPTMEN1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190046515-A1 | AMIDO THIADIAZOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2019-02-14 | — | — | US | disclosed |
| US-20190046515-A1 | AMIDO THIADIAZOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2019-02-14 | — | — | US | disclosed |
| US-10130619-B2 | Amido thiadiazole derivatives as NADPH oxidase inhibitors | GENKYOTEX SUISSE SA (CH) | 2018-11-20 | — | — | US | disclosed |
| US-20170348296-A1 | AMIDO THIADIAZOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SUISSE SA (CH) | 2017-12-07 | — | — | US | disclosed |
| US-20170348296-A1 | AMIDO THIADIAZOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SUISSE SA (CH) | 2017-12-07 | — | — | US | disclosed |
| US-20170348296-A1 | AMIDO THIADIAZOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SUISSE SA (CH) | 2017-12-07 | — | — | US | disclosed |
| EP-3233847-A1 | AMIDO THIADIAZOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GenKyoTex Suisse SA (CH) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016098005-A1 | AMIDO THIADIAZOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016098005-A1 | AMIDO THIADIAZOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2016-06-23 | — | — | WO | disclosed |
| EP-3034500-A1 | Amido thiazole derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2016-06-22 | — | — | EP | disclosed |
| EP-3034500-A1 | Amido thiazole derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2016-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170348296-A1 | AMIDO THIADIAZOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | NOX1, NOX5, CYBB | SLC6A9 4071/4885MAPT 1444/4885UTS2R 3726/4885 |
| US-20190046515-A1 | AMIDO THIADIAZOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | NOX1, NOX5, CYBB | SLC6A9 4071/4885MAPT 1444/4885UTS2R 3726/4885 |
| US-10130619-B2 | Amido thiadiazole derivatives as NADPH oxidase inhibitors | NOX1, NOX5, CYBB | SLC6A9 4071/4885MAPT 1444/4885UTS2R 3726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.